The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives
J Pers Med. 2021 Jun 2;11(6):499. doi: 10.3390/jpm11060499.
Michele Finotti1, Maurizio Romano1, Pasquale Auricchio2, Michele Scopelliti1, Marco Brizzolari1, Ugo Grossi1, Marco Piccino1, Stefano Benvenuti3, Giovanni Morana4, Umberto Cillo2, Giacomo Zanus1
Author information
14th Surgery Unit, Regional Hospital Treviso, DISCOG, University of Padua, 31100 Padua, Italy.
2Hepatobiliary Surgery and Liver Transplantation Unit, DISCOG, University of Padua, 35121 Padua, Italy.
3Gastroenterology Unit (IV), Cà Foncello Regional Hospital, 31100 Treviso, Italy.
4Division of Radiology, Treviso Regional Hospital, 31100 Treviso, Italy.
Abstract
Non-alcoholic fatty liver disease represents an increasing cause of chronic hepatic disease in recent years. This condition usually arises in patients with multiple comorbidities, the so-called metabolic syndrome. The therapeutic options are multiple, ranging from lifestyle modifications, pharmacological options, to liver transplantation in selected cases. The choice of the most beneficial one and their interactions can be challenging. It is mandatory to stratify the patients according to the severity of their disease to tailor the available treatments. In our contribution, we review the most recent pharmacological target therapies, the role of bariatric surgery, and the impact of liver transplantation on the NAFLD outcome.